# Diabetes Research Hub — Monitor Report
**Date:** 2026-04-17
**Previous report:** 2026-04-16
**Data sources:** hub_monitor.py output, clinical_trials_latest.json, pubmed_recent_latest.json, literature_gap_report.md, web search
**Run type:** Scheduled automated scan

---

## File System Status

All five key data files are present:

| File | Last Modified | Size | Status |
|------|-------------|------|--------|
| hub_monitor_report.md | 2026-04-16 07:05 | 4.8 KB | 1 day old — OK |
| clinical_trials_latest.json | 2026-04-16 07:05 | 514.3 KB | 1 day old — OK |
| pubmed_recent_latest.json | 2026-04-16 07:05 | 97.4 KB | 1 day old — OK |
| literature_gap_data.json | 2026-04-14 14:26 | 131.8 KB | 3 days old — OK |
| literature_gap_report.md | 2026-04-15 13:50 | 11.7 KB | 2 days old — OK |

**Hub-wide:** 708 files tracked (as of last hub_monitor.py run). 3 new files detected yesterday (clinical trials snapshot, PubMed snapshot, and previous monitor report). 28 modified files. 452 result files flagged as older than 14 days (historical snapshots and paper library — expected).

**No scripts need re-running today.** All data is within acceptable freshness. The Python scripts ran yesterday (April 16) and produced current snapshots. Next recommended script runs:
- `baseline_clinical_trials.py` — runs daily (next: auto tomorrow)
- `baseline_pubmed_alerts.py` — runs daily (next: auto tomorrow)
- `project1_literature_gap_analysis.py` — weekly recommended (next: ~2026-04-21)
- `hub_monitor.py` — runs daily (next: auto tomorrow)

---

## Clinical Trial Changes

**Overview:** 765 total unique trials tracked. 262 recruiting, 259 completed, 130 not yet recruiting, 109 active (not recruiting).

### Snapshot Diff (Apr 15 → Apr 16, from hub_monitor.py)

- **New trials: 3** (all completed — newly indexed, not new enrollments)
- **Status changes: 0**
- **Removed trials: 0**
- **New results posted: 0**

New trials added (all COMPLETED):
1. **NCT00690326** — Behavioral Change Communication for Physical Activity Among Females With T2D (Thiruvananthapuram Medical College)
2. **NCT05727579** — Dietary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR (Amsterdam UMC, Phase 4)
3. **NCT06206525** — Feasibility Trial Using an Inpatient Insulin Dosing Calculator (University of Washington)

None of these are high-priority for our research focus areas.

### Key Phase 3 Recruiting Trials — No Status Changes

All high-priority Phase 3 recruiting trials remain stable since last report:

| NCT ID | Trial | Sponsor | Status |
|--------|-------|---------|--------|
| NCT06832410 | VX-880 in T1D with Kidney Transplant | Vertex | RECRUITING Phase 3 |
| NCT04786262 | VX-880 in T1D | Vertex | RECRUITING Phase 3 |
| NCT07222137 | Baricitinib to Delay Stage 3 T1D (Adults) | Eli Lilly | RECRUITING Phase 3 |
| NCT07222332 | Baricitinib to Preserve Beta Cells (Children) | Eli Lilly | RECRUITING Phase 3 |
| NCT07076199 | Insulin Icodec (Weekly Insulin) | Novo Nordisk | RECRUITING Phase 3 |
| NCT07088068 | Teplizumab (new study) | Sanofi | RECRUITING Phase 3 |
| NCT07258394 | Dimethyl Fumarate for β-Cell Function in T1D | Nanjing Medical | RECRUITING Phase 3 |

**Trials in ACTIVE_NOT_RECRUITING (results expected soon):**
- NCT06913895 — Tirzepatide in T1D (Eli Lilly, Phase 3)
- NCT06962280 — Long-Term Tirzepatide in T1D with Overweight (Eli Lilly, Phase 3)
- NCT05929079 — Retatrutide in T2D (Eli Lilly, Phase 3)
- NCT05791201 — VX-264 Encapsulated Islets in T1D (Vertex, Phase 1/2)

---

## PubMed Highlights

**Overview:** 127 unique papers across 15 alert domains (30-day window). 28 new papers and 28 dropped papers in the Apr 16 snapshot vs. Apr 15.

### Cross-Domain Papers (5 new today — highest priority)

From the hub_monitor.py snapshot diff:

1. **[41986815] "Multi-tissue multi-omics integration reveals tissue-specific pathways, gene networks and drug candidates for type 1 diabetes"** — Domains: Drug Repurpose + Multi-Omics. Published in *Diabetologia*. **HIGH PRIORITY: Directly hits TWO Tier 1 areas (Multi-Omics Biomarker Integration + Drug Repurposing).** Action: Retrieve full abstract and assess for inclusion in analysis pipeline.

2. **[41985330] "Multi-strain probiotic enhances metformin tolerance by modulating gut microbiome and bile acid pathways"** — Domains: Microbiome + Multi-Omics. Relevant to Tier 2: Microbiome-Metabolic Pathway Analysis.

3. **[41982769] "Dietary fiber supplementation mitigates gestational diabetes risk and preterm birth via gut microbiota"** — Domains: Biomarker + Microbiome.

4. **[41982276] "Association Between the Lactate-to-Albumin Ratio and ICU/In-Hospital Mortality in Critically Ill Patients"** — Domains: AI/ML + Biomarker.

5. **[41983640] "Diagnosis of Mucormycosis: Current Situation, Challenges and Future Prospects"** — Domains: AI/ML + Biomarker.

### Other Notable New Papers

- **[41986506] "Deep single-cell decoding of human pancreatic islets reveals T2D β-cell gene expression defects"** — Published in *The EMBO Journal*. High-impact finding on beta cell biology.
- **[41986697] "Structure-centric searching enables global mapping of the public metabolome"** — Published in *Nature Biotechnology*. Potentially valuable tool for our Multi-Omics pipeline.
- **[41986680] "Dozens of AI disease-prediction models were trained on dubious data"** — Published in *Nature*. Methodological caution paper relevant to our AI/ML standards per Research Doctrine.

### Domain Volume Trends

LADA (3 papers), Drug Repurposing (5 papers), and Epigenetics (8 papers) continue showing low publication volume — consistent with gap analysis findings. AI/ML (177 papers) and GLP-1 (157 papers) remain highest-volume domains.

### Key Therapy Mentions

No papers in the current 30-day window mention zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, or teplizumab in titles. This is a title-only search limitation — previous report recommended expanding to abstract matching.

---

## Gap Analysis Summary

**Data freshness:** Gap data from 2026-04-14 (3 days old); gap report from 2026-04-15. Both current.

### Top 5 Potentially Meaningful Research Gaps

| Rank | Domain 1 | Domain 2 | Gap Score | Joint Pubs | Rationale |
|------|----------|----------|-----------|------------|-----------|
| 1 | Beta Cell Regen | Health Equity | 100.0 | 0 | Regenerative therapies must address access equity |
| 2 | Insulin Resistance | Islet Transplant | 100.0 | 1 | IR affects graft survival; barely studied |
| 3 | Islet Transplant | Drug Repurposing | 100.0 | 0 | Computational drug screening not applied to islet protection |
| 4 | Islet Transplant | Health Equity | 100.0 | 0 | Islet transplant available only at select centers |
| 5 | Gene Therapy | LADA | 100.0 | 0 | LADA's autoimmune mechanism is a gene therapy candidate |

### Alignment with Tier 1 Areas

- **Islet Transplant × Drug Repurposing** (Gap #3) → Maps directly to Tier 1 Drug Repurposing. Our islet repurposing analysis (completed; see `islet_repurposing_report.md`) addresses this gap.
- **Drug Repurposing × Health Equity** → Drug repurposing could yield more affordable treatments. Relevant given today's generic dapagliflozin approval news (see Breaking News).
- **Drug Repurposing × LADA** → Systematic repurposing screens for LADA-specific therapies don't exist. Low publication volume in both domains confirms this gap is real.

---

## Breaking News (Web Search — Last 7 Days)

### Significant Findings

1. **GLP-1 Resistance Discovery (Stanford, April 11, 2026)**
   Genetic variants carried by ~10% of the general population cause "GLP-1 resistance" — higher GLP-1 levels but reduced biological effectiveness. Two variants in the PAM enzyme (peptidyl-glycine alpha-amidating monooxygenase) impair GLP-1 activation. Meta-analysis of 3 trials (1,119 participants) showed carriers had lower HbA1c response to GLP-1 RA drugs. Published in *Genome Medicine*.
   **Relevance:** HIGH — Directly impacts our GLP-1 monitoring domain and AI/ML prediction work. A GLP-1 pharmacogenomics angle is an unexplored intersection (connects to our GWAS/Polygenic domain). Consider adding a "GLP-1 pharmacogenomics" alert.
   *Evidence level: 2b (multi-study meta-analysis + mechanistic work)*

2. **GLP-1 RA Cardiovascular/Kidney Benefits in T1D (Johns Hopkins, April 14, 2026)**
   175,000-patient EHR study published in *Nature Medicine* showed GLP-1 RAs reduce major cardiovascular events by 15% and end-stage kidney disease by 19% in type 1 diabetes patients, without increased safety concerns. Heart attack risk reduced 21%; all-cause mortality reduced 16%.
   **Relevance:** HIGH — This is the largest study of GLP-1 RAs in T1D. Directly relevant to our clinical trial monitoring (NCT05819138 — Semaglutide CV Outcomes in T1D). Suggests GLP-1 benefit extends beyond T2D.
   *Evidence level: 2b (large retrospective cohort)*

3. **Awiqli (Insulin Icodec) — FDA Approved March 26, 2026**
   Novo Nordisk's once-weekly basal insulin approved for T2D. First weekly insulin; reduces injections from 365 to 52 per year. Based on four Phase 3 ONWARDS trials (n=2,680). Available in US second half of 2026.
   **Relevance:** Updates our trial tracker — NCT07076199 (Icodec Phase 3) should be flagged as related to an FDA-approved product. Major Health Equity implications (reduced injection burden).
   *Evidence level: 1a (Phase 3 program + FDA regulatory action)*

4. **Diabetes UK Professional Conference (April 22-24, 2026, Liverpool)**
   Upcoming. Watch for new data presentations relevant to our monitoring domains.

### Previously Reported (Still Current)

- **Orforglipron (Foundayo) FDA Approved** — April 1, 2026. First oral small-molecule GLP-1 RA. (Reported in Apr 16 report; tracker update recommended.)
- **Generic Dapagliflozin FDA Approved** — April 7, 2026. First SGLT2 inhibitor generic. (Reported in Apr 16 report.)

---

## Snapshot Comparison Summary (vs. Baseline 2026-03-15)

Since the March 15 baseline snapshot:
- Total trials: 746 → 765 (+19 new trials indexed)
- Recruiting: 254 → 262 (+8)
- Completed: 244 → 259 (+15)
- Results posted: 245 → 260 (+15)
- Phase 3 recruiting: 42 → 44 (+2)

Key new Phase 3 entries since baseline include the Dimethyl Fumarate T1D trial (NCT07258394) and additional Lilly/Novo Nordisk pipeline trials.

---

## Recommended Actions

### Immediate (Today)

1. **Retrieve full abstract for PMID 41986815** — "Multi-tissue multi-omics integration reveals tissue-specific pathways, gene networks and drug candidates for type 1 diabetes" (Diabetologia). This paper hits two Tier 1 areas and is the highest-priority new finding this cycle.

2. **Add GLP-1 resistance finding to Research Findings Summary.** The Stanford PAM variant discovery is significant for our GLP-1 monitoring. This connects GLP-1 response to genetics (GWAS/Polygenic domain intersection) — a gap our analysis flagged.

### This Week

3. **Update Research Tracker with three FDA approvals:**
   - Awiqli (insulin icodec) — approved March 26
   - Foundayo (orforglipron) — approved April 1
   - Generic dapagliflozin — approved April 7

4. **Add Johns Hopkins T1D GLP-1 study to evidence base.** Published in *Nature Medicine* — this is Level 2b evidence supporting GLP-1 benefit in T1D. Link to our tracked trial NCT05819138.

5. **Review the Nature paper on dubious AI training data** (PMID 41986680). This has implications for our AI/ML prediction methodology standards per Research Doctrine.

### When Convenient

6. **Consider adding a "GLP-1 pharmacogenomics" alert domain** — the Stanford GLP-1 resistance paper reveals a GWAS/Polygenic × GLP-1 intersection that our gap analysis would flag as high-value.

7. **Expand PubMed keyword search to abstract matching** — current title-only search returns 0 hits for all six key therapies. This was recommended in the Apr 16 report and remains outstanding.

8. **Watch for Diabetes UK Professional Conference outputs** (April 22-24) — may produce actionable data next week.

9. **No scripts need re-running today.** All data files are current. Gap analysis refresh recommended ~April 21.

---

## Daily Iteration Results (Run #5)

### Paper Vetting: 15 papers processed
- **12 VETTED** (on-topic, PMID verified against paper_library abstracts)
- **3 FLAGGED** as off-topic: 19237585 (epilepsy), 20519905 (sepsis), 20570966 (Crohn's)
- 2 noted as tangential immunology background: 19169263 (Tregs/stroke), 20336151 (TH2 responses)
- Cumulative: ~60 of ~267 papers vetted (22.5%)

### Path Validation: 4 paths validated (all HIGH confidence)
1. **metformin → inflammation** — VALIDATED. Inflammopharmacology 2025 confirms AMPK/NLRP3 mechanism.
2. **NLRP3 inflammasome → inflammation** — VALIDATED. Frontiers in Immunology 2025 + meta-analysis (14,300 patients).
3. **oxidative stress → inflammation** — VALIDATED. Chinese Medical Journal 2025 confirms ROS-NF-κB vicious cycle.
4. **teplizumab → T1D** — VALIDATED. NEJM 2024 RCT + 2026 real-world data (42 patients, 17% progression at 1yr).

Cumulative paths validated: ~31 of 48 (64.6%)

### Credibility Sweep: CLEAN
No fabricated PMIDs, no overstatements, no problematic language found.

### Notes
- Pipeline rebuild completed: all 39 scripts [OK], verify_before_deploy: 33/33 VERIFIED, 0 issues
- Removed stale legacy dashboard (Islet_Drug_Repurposing.html) superseded by Drug_Repurposing_Islet.html
- agent_state.json updated with all results and reprioritized work queue
- 3 flagged off-topic papers should be reviewed for removal from the corpus in a future cleanup pass

---

*Generated by automated monitor task — 2026-04-17*
*Data integrity: All five key files present and read successfully. Snapshot comparison performed. Web search completed for breaking news.*
*Iteration run: 15 papers vetted, 4 paths validated, credibility sweep clean. Pipeline rebuild: 39/39 OK, 33/33 dashboards verified.*
